RAP-103

• Description :

  RAP-103 is an orally active CCR antagonist that provides potent synaptic protection by inhibiting and reversing cytoskeletal changes induced by PrPC/NOX signaling. RAP-103 is potentially useful in Alzheimer's disease (AD) research[1].

• UNSPSC :

  12352209

• Target :

  CCR

• Related Pathways :

  GPCR/G Protein; Immunology/Inflammation

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Neurological Disease

• Smiles :

  C[C@H](O)[C@H](C(O)=O)NC([C@@H](CC1=CC=C(O)C=C1)NC([C@@H](CC(N)=O)NC([C@@H]([C@@H](O)C)NC([C@@H]([C@@H](O)C)N)=O)=O)=O)=O

• Molecular Formula :

  C25H38N6O11

• Molecular Weight :

  598.60

• References & Citations :

  [1]Kuhn TB, et al. Chemokine Receptor Antagonists Prevent and Reverse Cofilin-Actin Rod Pathology and Protect Synapses in Cultured Rodent and Human iPSC-Derived Neurons. Biomedicines. 2024 Jan 1;12 (1) :93.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Peptides

• Clinical Information :

  No Development Reported

• CAS Number :

  [1337998-99-8]